Alkeus Pharmaceuticals, Inc.的动态

No matter the phase of your project, from pilot study to Phase IV post-market study, MERIT provides the expertise and technology to help you achieve your development goals. We seamlessly manage the imaging components of your trial, creating efficiencies for your #drugdevelopment. Check out summaries of two of our #ophthalmology case studies to learn more: https://lnkd.in/dPrVxdHZ #MERITCRO #YourClinicalEndpointExpert #clinicaltrials #clinicalresearch #casestudy #imagingsolutions

Lightview Capital sells Array to WCG: A strategic move in clinical research solutions #LightviewCapital #Array #WCG #ClinicalResearch #LifeSciences #PrivateEquity #BusinessServices #TechSolutions #EventTechnology

A few thoughts from the top of the morning here: In just a little over a year, J&J has gone from Mr./Mrs. Irrelevant to perhaps the compelling suite of products in the Cardiac/Vascular market. Pretty Impressive. Hopefully J&J continues to leave Abiomed alone, and does so with Shockwave...a la what they did w/ Biosense Webster. If they go in and J&J'ify everything, innovation will stop faster than a production line with a wrench tossed in it's gears. If Shockwave's acquisition of Neovasc, a coronary sinus reducer for refractive angina ever bears any fruit...$13.1 B will seem like a song for this acquisition. J&J means business this time. They have often said they wanted to become a major player again in Cardiac/Vascular, dating back to their once imminent acquisition of Guidant. But actions speak louder than words. They are likely far from done. Percutaneous valve technologies are the glaring omission from their shiny new product portfolio. An acquisition of Edwards would be the lynch pin here, striking fear in the hearts and minds of Hospital Purchasing execs across America. Or maybe they start small, acquiring some of the earlier stage companies that are showing positive results from first in man trials across the various markets: Aortic, Mitral & Tricuspid? Maybe they look at the one "non strategic owned" commercial stage perc valve company on the market as an entry point? Time will tell, fun to speculate...

Are you curious to see the latest image analysis and image management software from #IndicaLabs? Book a meeting today with the team attending #AACR2024! #digitalpathology #imageanalysis

The Power of Visualization: "On some level, the brain must be processing wellness rather than illness." Click for more https://bsapp.ai/lCra4Dfe3 #link #strokerecovery #Imagination #empathy #meditation #mentalimagery #actionobservation #pharmaceuticals #wellbeing #nitricoxide #mirrorneuronsystem #belief #mindbody #visualization #expectation #emotionalstyle #kindness #stress #longevity #mentalpractice #physical #oxytocin #physicalstrength #insights #placeboeffects #love #physicaleffects #victorydancing #compassion. #cardiovascularhealth #visualization

During the Clinical Trials Imaging Accuracy Crisis Panel Discussion at?#AACI?#CRI2024, Kira Pavlik, Associate Director of Clinical Trials Operations at the Yale Cancer Center, delves into the complexities of FDA inspections and the meticulous processes involved in bringing new drugs to market. Hear firsthand experiences of navigating rigorous reviews, the importance of detailed documentation, and the global impact of ensuring drug efficacy and safety: https://zurl.co/fYoW #clinicaltrials #clinicaltrialimagingworkflow #imagingworkflow #pharma #regulatory

Johnson & Johnson announced their acquisition of Shockwave Medical for $13.1 billion in April 2024. - You're a pre-commercial start-up in the same space. What do you do? How does this affect you? Does this validate the market or make it more difficult? Do you have to change your commercialization strategy? Do you have to accelerate? - That's the thing about the team at Amplitude Vascular Systems. They are a pre-commercial start-up. But they don't act like it. We dig into one of the biggest stories in medical devices this year with Sean Gilligan and Robert Chisena. - MassMEDIC Boyd Biomedical

A recent review of our CNS methods showed that we include 99.4% of collected data from the NeuroCart, PainCart and TMS in the analysis. This is a great achievement for our test batteries and our dedicated Method Execution and Biomarker Engineering & Analytics team! To get the margin of error even further below 0.6%, these teams frequently meet to discuss improvements on the hardware, software and staff training modules. Congratulations to both teams on their commendable achievements! #clinicalresearch #clinicaldata

We’re thrilled to co-lead Power's $12M Series A, alongside our friends Nikhil Basu Trivedi at Footwork and Kin Ventures. Patient recruitment is a massive bottleneck in clinical trials. 86% of U.S. trials are delayed due to lack of enrollment. Yet <5% of American patients participate in potentially life-changing trials. Many must advocate for themselves, wrestling with dense jargon, unclear tradeoffs, and an opaque enrollment process. Power is reimagining trial recruitment starting with a patient-led marketplace. Therapeutic options should be easily accessible for everyone — regardless of geographical location, ethnicity, or socioeconomic background. Unlocking access for patients is only act one. We believe Power has the potential to redefine how patients, researchers, and life science partners interact in the clinical trial system.

Make informed decisions regarding how much medication to produce before patients are screened, medication has been ordered, and packaging designs/protocols have been finalized. Learn about Calyx Supply Simulation in this blog. https://lnkd.in/gepaJa6p #IRT #RTSM #ClinicalTrials #TrialSupplyManagement #Randomization #ChooseCalyx Malcolm Morrissey